TY - JOUR
T1 - Beyond Prostate Imaging Reporting and Data System
T2 - Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer
AU - Emmett, Louise
AU - Papa, Nathan
AU - Hope, Thomas A.
AU - Fendler, Wolfgang
AU - Calais, Jeremie
AU - Burger, Irene
AU - Eiber, Matthias
AU - Barbato, Francesco
AU - Moon, Daniel
AU - Counter, William
AU - John, Nikeith
AU - Xue, Alan
AU - Franklin, Anthony
AU - Thompson, James
AU - Rasiah, Kris
AU - Frydenberg, Mark
AU - Yaxley, John
AU - Buteau, James
AU - Agrawal, Shikha
AU - Ho, Bao
AU - Nguyen, Andrew
AU - Liu, Victor
AU - Lee, Jonathan
AU - Woo, Henry
AU - Hsiao, Edward
AU - Sutherland, Thomas
AU - Perry, Elyse
AU - Stricker, Phillip
AU - Hofman, Michael S.
AU - Kasivisvanathan, Veeru
AU - Roberts, Matthew
AU - Murphy, Declan
N1 - Publisher Copyright:
© 2024 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.
PY - 2024/8/1
Y1 - 2024/8/1
N2 - Purpose:The Prostate Imaging Reporting and Data System (PI-RADS) score is standard of care for clinically significant prostate cancer (csPCa) diagnosis. The PRIMARY score (prostate-specific membrane antigen [PSMA]-positron emission tomography [PET]/CT) also has high diagnostic accuracy for csPCa. This study aimed to develop an easily calculated combined (P) score for csPCa detection (International Society of Urological Pathology [ISUP] ≥2) incorporating separately read PI-RADS and PRIMARY scores, with external validation.Materials and Methods:Two datasets of men with suspected PCa, no prior biopsy, recent MRI and 68Ga-PSMA-11-PET/CT, and subsequent transperineal biopsy were evaluated. These included the development sample (n = 291, 56% csPCa) a prospective trial and the validation sample (n = 227, 67% csPCa) a multicenter retrospective database. Primary outcome was detection of csPCa (ISUP ≥2), with ISUP ≥ 3 cancer detection a secondary outcome. Score performance was evaluated by area under the curve, sensitivity, specificity, and decision curve analysis.Results:The 5-point combined (P) score was developed in a prospective dataset. In the validation dataset, csPCa was identified in 0%, 20%, 52%, 96%, and 100% for P score 1 to 5. The area under the curve was 0.93 (95% CI: 0.90-0.96), higher than PI-RADS 0.89 (95% CI: 0.85-0.93, P =.039) and PRIMARY score alone 0.84 (95% CI: 0.79-0.89, P <.001). Splitting scores at 1/2 (negative) vs 3/4/5 (positive), P score sensitivity was 94% (95% CI: 89-97) compared to PI-RADS 89% (95% CI: 83-93) and PRIMARY score 86% (95% CI: 79-91). For ISUP ≥ 3, P score sensitivity was 99% (95% CI: 95-100) vs 94% (95% CI: 88-98) and 92% (95% CI: 85-97) for PI-RADS and PRIMARY scores respectively. A maximum standardized uptake value > 12 (P score 5) was ISUP ≥ 2 in all cases with 93% ISUP ≥ 3.Conclusions:The P score is easily calculated and improves accuracy for csPCa over both PI-RADS and PRIMARY scores. It should be considered when PSMA-PET is undertaken for diagnosis.
AB - Purpose:The Prostate Imaging Reporting and Data System (PI-RADS) score is standard of care for clinically significant prostate cancer (csPCa) diagnosis. The PRIMARY score (prostate-specific membrane antigen [PSMA]-positron emission tomography [PET]/CT) also has high diagnostic accuracy for csPCa. This study aimed to develop an easily calculated combined (P) score for csPCa detection (International Society of Urological Pathology [ISUP] ≥2) incorporating separately read PI-RADS and PRIMARY scores, with external validation.Materials and Methods:Two datasets of men with suspected PCa, no prior biopsy, recent MRI and 68Ga-PSMA-11-PET/CT, and subsequent transperineal biopsy were evaluated. These included the development sample (n = 291, 56% csPCa) a prospective trial and the validation sample (n = 227, 67% csPCa) a multicenter retrospective database. Primary outcome was detection of csPCa (ISUP ≥2), with ISUP ≥ 3 cancer detection a secondary outcome. Score performance was evaluated by area under the curve, sensitivity, specificity, and decision curve analysis.Results:The 5-point combined (P) score was developed in a prospective dataset. In the validation dataset, csPCa was identified in 0%, 20%, 52%, 96%, and 100% for P score 1 to 5. The area under the curve was 0.93 (95% CI: 0.90-0.96), higher than PI-RADS 0.89 (95% CI: 0.85-0.93, P =.039) and PRIMARY score alone 0.84 (95% CI: 0.79-0.89, P <.001). Splitting scores at 1/2 (negative) vs 3/4/5 (positive), P score sensitivity was 94% (95% CI: 89-97) compared to PI-RADS 89% (95% CI: 83-93) and PRIMARY score 86% (95% CI: 79-91). For ISUP ≥ 3, P score sensitivity was 99% (95% CI: 95-100) vs 94% (95% CI: 88-98) and 92% (95% CI: 85-97) for PI-RADS and PRIMARY scores respectively. A maximum standardized uptake value > 12 (P score 5) was ISUP ≥ 2 in all cases with 93% ISUP ≥ 3.Conclusions:The P score is easily calculated and improves accuracy for csPCa over both PI-RADS and PRIMARY scores. It should be considered when PSMA-PET is undertaken for diagnosis.
KW - PET
KW - diagnosis
KW - multi-parametric MRI
KW - prostate cancer
KW - prostate specific membrane antigen
UR - http://www.scopus.com/inward/record.url?scp=85198677592&partnerID=8YFLogxK
U2 - 10.1097/JU.0000000000004010
DO - 10.1097/JU.0000000000004010
M3 - Article
C2 - 38758680
AN - SCOPUS:85198677592
SN - 0022-5347
VL - 212
SP - 299
EP - 307
JO - Journal of Urology
JF - Journal of Urology
IS - 2
ER -